BridgeBio Pharma stock finds support near USD 66

Published on 09/23/2026 at 07:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BridgeBio Pharma stock traded at USD 66.85 on September 22, 2026, below its USD 90.17 yearly high. Revenue reached USD 502.08 million in fiscal 2025.

BBIO, US10806X1028, Illustration mit AI erstellt.

BridgeBio Pharma Inc. (US10806X1028) traded at USD 66.85 on September 22, 2026, while its 52-week range stretched from USD 49.00 to USD 90.17. The stock was near a potential support area around USD 66, according to TheStreet on September 22, 2026.

Support near USD 66

The latest available market snapshot places BridgeBio Pharma at a market capitalization of USD 13.02 billion and volume of 3,155,883 shares. The USD 66.85 price was 25.9 percent below the 52-week high of USD 90.17 and USD 17.85 above the 52-week low of USD 49.00, showing that the stock remained closer to its annual floor than its peak.

The support thesis is technical rather than a confirmed change in the company's fundamentals. TheStreet described the area around USD 66 as a possible floor but also noted that the position was being sized cautiously because support had not yet been proven.

Revenue growth meets heavy losses

BridgeBio reported revenue of USD 502.08 million in fiscal 2025, but net loss reached USD 724.93 million in the same fiscal year, according to Pluang. The comparison between revenue and net loss highlights the central operating tension: commercial progress has not yet translated into positive earnings.

The same source reports long-term debt of USD 1.72 billion and negative operating cash flow. These figures are dated to fiscal 2025 in the available company snapshot and are historical context rather than a newly reported interim quarter.

Analyst targets remain higher

TheStreet reported on September 22, 2026, that TipRanks data for 14 best-performing analysts showed an average 12-month target of USD 108.92, with a high of USD 130.00 and a low of USD 94.00. Against the recent price near USD 68, the average target implied more than 60 percent upside, although that comparison reflects analyst expectations rather than a guaranteed outcome.

The distance between the market price and analyst targets is substantial: USD 108.92 was USD 42.07 above the USD 66.85 quoted price, a difference of 62.9 percent. The counter-factor is execution risk, because the fiscal 2025 loss, negative operating cash flow and debt burden leave the valuation dependent on successful pipeline commercialization.

Stock remains below yearly high

BridgeBio Pharma stock stood at USD 66.85 on September 22, 2026, on the Nasdaq. Its USD 13.02 billion market capitalization, USD 49.00 to USD 90.17 52-week range and fiscal 2025 revenue of USD 502.08 million provide the key reference points for the current valuation discussion.